OTC Monograph Reform Proposal Offers Two-Tier Approach
This article was originally published in The Rose Sheet
Executive Summary
One tier could provide two-year exclusivity, should FDA request clinical trials for new conditions or ingredients, under a US Senate discussion draft. Essentially stalled monograph process would be replaced by deadlines for FDA action in under two years.
You may also be interested in...
US FDA Announces OTC Monograph Drug User Fee Rates, Giving 45 Days For First Facility Payments
The FDA says the new OTC monograph drug user-fee program (OMUFA) will provide additional resources needed to support the streamlined regulatory activities described by OTC drug reform legislation enacted in March 2020.
Senate Health Committee To Move On Cosmetics; News In Brief
Cosmetics reform legislation is slated for markup April 18, according to Senate Health Committee leadership. In other news, ECHA continues working to support 2018 REACH registrants, and IFRA North America names a new chief regulatory scientist and communications director.
Rep. Pallone Galvanized By FDA's 'Troubling Overview' Of Cosmetic Imports
FDA physically inspected less than 1% of the 2.9m cosmetic imports that reached the US in fiscal 2016, according to a letter from the agency released by Congressman Frank Pallone. The ranking member of the House Energy and Commerce Committee says he's aiming for a hearing in September on his bipartisan proposal to increase FDA's authority over the cosmetics sector.